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GuidelinesHead and neck cancer (HNC) is a disease of the upper aerodigestive tract and is one of the most frequently
diagnosed cancers worldwide. A high rate of cancers involving the head and neck are reported across the
Asian region, with notable variations between countries. Disease prognosis is largely dependent on tumor
stage and site. Patients with early stage disease have a 60–95% chance of cure with local therapy. Early
diagnosis and appropriate treatment are important to increase the likelihood of cure and survival. How-
ever, the majority of patients present with locally advanced disease and require multimodality treatment.
This necessitates, a multidisciplinary approach which is essential to make appropriate treatment deci-
sions, particularly with regards to tolerability, costs, available infrastructure and quality of life issues.
Unfortunately, majority of the studies that dictate current practice have been developed in the west
where diseases biology, patient population and available infrastructure are very different from those in
the Asian continent. With this in mind an expert panel of Head and Neck Oncologists was convened in
May 2012 to review the National Comprehensive Cancer Network (NCCN) and the European Society
for Medical Oncology (ESMO) clinical practice guidelines and develop practical recommendations on
the applicability of these guidelines on the management of head and neck cancer for Asian patients.
The objective of this review and consensus meeting was to suggest revisions, to account for potential dif-
ferences in demographics and resources, to the NCCN and ESMO guidelines, to better reﬂect current clin-
ical management of head and neck cancer within the Asian region for health care providers. These
recommendations, which reﬂect best clinical practice within Asia, are expected to beneﬁt practitioners
when making decisions regarding optimal treatment strategies for their patients.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.niversity
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Head and neck cancers (HNC) involve various malignancies of
the upper aerodigestive tract and are one of the most frequently
diagnosed cancers worldwide.1 These cases include cancers of the
lip, oral cavity, oropharynx, larynx, hypopharynx, salivary glands,
nasopharynx, nose, paranasal sinus, and middle ear. For the pur-
pose of this review, we focused on tumors originating from the
squamous lining of the upper aerodigestive tract (i.e. excluding
cancers of the paranasal sinus and salivary gland).
The vast majority of HNC cases occur in Asia and South East
Asia. In addition, there are also epidemiological differences in the
occurrence of the disease in the Eastern hemisphere. Globally, over
260,000 cancers of the oral cavity were diagnosed in 2008.2 There
appears to be a wide variation in the incidence of oral cancer with-
in the Asian region; South-Central Asia had among the highest
rates of oral cavity cancers (9.4/100,000 in males and 5.5/100,000
in females) while the lowest rates were documented in Eastern
Asia (2.1/100,000 in males and 0.9/100,000 in females).2
The Asian region also has the highest rates of nasopharyngeal
cancersworldwide.2 TheGLOBOCAN2008 record (Fig 1), shows that
Asian countries feature amongst the 20 highest Age-World-Stan-
dardized incidence Rate [ASR (W)] values worldwide.3While epide-
miological data indicates a declining incidence in males over the
past decade, the incidence of HNC has remained stable in females.1
Historically, alcohol and tobacco consumption are well estab-
lished risk factors for HNC.1 While tobacco and alcohol abuse are
the major risk factors for these tumors worldwide,4 chewed tobac-
co, betel nut, beedi smoking and Epstein Barr virus (EBV) are aeti-
ological agents that are speciﬁc to Asia that result in an increased
incidence of HNCs in this region of the world.5 However, more re-
cent evidence demonstrates a link between human papillomavirus
(HPV) types 16 and 18 and HNCs, particularly oropharyngeal can-
cers6 and laryngeal carcinoma, and HPV 31 in nasopharyngeal car-
cinoma (NPC).6 For nasopharyngeal cancer, independent risk
factors have been identiﬁed which include Southern Chinese
ancestry, exposure to the EBV7 and consumption of salted ﬁsh.8
While lifestyle factors and tumor biology have an impact on
outcomes, disease prognosis is largely dependent on tumor stage
and site.9 The majority (90%) of HNC belong to the Squamous Cell
Carcinoma (SCC) histological subtype which represents a wideFigure 1. 2008 GLOBOCAN age-world-standardizespectrum of neoplasms with differing natural histories, prognosis
and clinical responses.9 SCC of the head and neck (SCCHN) primar-
ily present as locoregionally advanced (stage III or IV) cancers,
which have cure rates ranging from 30% to 40% despite multi
modality therapy.10 There is also signiﬁcant morbidity associated
with treatment, with more than 50% risk of recurrence or develop-
ment of distant metastases.11 Patients with early stage disease
have a 60–95% chance of cure with local therapy,9 and early diag-
nosis and treatment is associated with an increased likelihood of
cure or increased survival.12
The objective of this consensus meeting was to review the cur-
rent National Comprehensive Cancer Network (NCCN) V2 201113
and the European Society for Medical Oncology (ESMO) 20101 clin-
ical practice guidelines, and to suggest revisions, to account for po-
tential difference in demographics and resources, to better reﬂect
current clinical management of head and neck cancer within the
Asian region for health care providers. These recommendations,
which reﬂect best achievable clinical practice within Asia, are ex-
pected to beneﬁt practitioners when making decisions regarding
optimal treatment strategies for their patients.Current guidelines
The management of patients with HNC is complex, and a mul-
tidisciplinary approach, as advocated by the NCCN and the ESMO
clinical practice guidelines, is required.1,13 Ideally management
should be tailored according to tumor characteristics, patient pop-
ulation and Multidisciplinary Team (MDT) expertise and prefer-
ences.14 The goals of treatment in patients with HNC are
threefold: (1) ablation of cancer with minimal morbidity, (2) pres-
ervation and restoration of function, and (3) to maximize quality of
life.14 Over the past decade, an organ-preservation approach has
gained greater attention in the management of these patients.
The ESMO guidelines advocate that a diagnosis of HNC is based
on the World Health Organization classiﬁcation from a surgical
biopsy sample.1,15 Current tumor classiﬁcation is based upon mor-
phology and anatomic distribution. For all tumor subsites, clinical
staging should involve physical examination, including head and
neck endoscopy whenever needed, computed tomography (CT)
scan and or magnetic resonance imaging (MRI) and chest X-
ray.1,10 A thoracic CT scan may be performed to rule out metastaticd incidence rate of nasopharyngeal cancers.3
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according to the TNM system of the American Joint Committee on
Cancer (AJCC) 7th Edition, in which T4 tumors are subdivided into
T4a moderately advanced and T4b very advanced. Stage IV is sub-
divided into stages IVa and IVb accordingly, and stage IVc for met-
astatic disease.
Treatment is dependent upon the primary tumor location and
extension.1 Patients with stage I–II tumors, are generally treated
with a single modality, either conservative surgery or radiother-
apy.1,14 Unfortunately, at the time of diagnosis, the majority of pa-
tients have stage III or IV disease.14 Multimodal therapy involving
proper combinations of surgery, radiation and/or chemotherapy is
the standard of care for these patients. Despite aggressive primary
treatment, locoregional relapse accounts for approximately 80% of
treatment failures. Following disease progression, distant metasta-
ses most often involve the lungs, and at the time of death up to 30%
of patients have clinically detectedmetastases.12 Surgery or re-irra-
diation may be considered in selected cases of localized recurrence.
However, for most patients, palliative care with or without chemo-
therapy is the standard treatment option for recurrent disease.1,14
Methodology
The Asia Paciﬁc Head and Neck Cancer expert panel included 22
participants from 11 Asian countries. All participants, comprising
of surgical, radiation and medical oncologists, represent HNC man-
agement experts from across the Asia–Paciﬁc region, to provide for
uniformity. The participants were divided into 4 working groups
based on area of expertise and assigned to one of the following
groups:
1. Lip and oral cavity
2. Oropharynx
3. Hypopharynx and larynx
4. Nasopharynx.
Each group consisted of 5–6 participants who debated and dis-
cussed the NCCN V2 201113 and ESMO 2010 HNC management
guidelines,1 for the particular subsite and formed recommenda-
tions for adapting these guidelines to Asian clinical practice. Each
group presented their individual recommendations before the en-
tire expert panel and the group developed consensus recommen-
dations for Asian clinical practice by voting for or against the
individual group conclusions. The content of this article is the out-
come of this expert panel discussion.
Recommendations for HNC management in Asian patients
TheNCCNandESMOgroupshavedevelopeda comprehensive set
of guidelines for the management of HNC. There was an overall
agreement with these international guidelines amongst the group,
however, the Asian expert panel made some revisions for the man-
agement of HNC based on real-world circumstances in Asia. For all
the subsites discussed below, the main framework is drawn from
the NCCN guidelines, which are more comprehensive and provide
greater clarity for adoption in day-to-day clinical practice. However,
the ESMO guidelines were used as a consensus summary guideline,
and special reference is made to these guidelines when applicable.
At all stages, a MDT approach with cross-specialty representation
and opinion sharing at tumor boards was strongly advocated.
General trends
Although a 3-weekly cisplatin regimen is recommended in the
published literature, in routine clinical practice in Asia, a weeklycisplatin regimen (30–40 mg/m2) given concurrently with radio-
therapy (RT) is routinely administered as an alternative, aiming
for a cumulative dose of 200 mg/m2 along with radiotherapy. This
recommendation is based on common practice and clinician
preference.
In some settings, the original NCCN recommendation of RT
combined with cisplatin/chemotherapy has been replaced by RT
plus systemic therapy, to include the anti-epidermal growth factor
receptor (EGFR) targeted monoclonal antibody cetuximab. In addi-
tion to clinical experience, this revision is suggested based on the
ESMO guidelines, which clearly indicate that combined concomi-
tant chemoradiotherapy (CCRT) may be associated with greater
toxicity, compared to cetuximab plus RT, and the beneﬁcial effects
of CCRT in elderly patients are also questionable, for locally ad-
vanced SCCHN. This was collectively accepted and agreed upon
by the group wherever relevant. In the absence of direct compara-
tive trials between CCRT and cetuximab plus RT, the group agreed
that it would be considered most appropriate to consider both the
treatment modalities as effective options. However, cisplatinum
CCRT is the preferred treatment whenever tolerated, due to higher
level of supporting evidence, clinical experience and cost
implications.
Access to and use of positron emission topography (PET) and
intensity-modulated radiotherapy (IMRT) is limited to the major
oncology healthcare facilities across the Asia–Paciﬁc region. There-
fore, unless the superiority of this diagnostic or radiation technol-
ogy is established in the clinical setting and supported by
literature, the expert group decided against strongly recommend-
ing one modality over standard or conventional methods.
Lip
Stage I and II
The expert panel recommendations differ slightly from the
NCCN V2, 2011 guidelines for stage I and II lip cancer. In Asian clin-
ical practice, excision may not be the upfront and best approach,
with regard to functional and cosmetic results, due to non avail-
ability of specialized reconstructive surgeon and availability of
infrastructure; MDT discussion, keeping patient preference in
mind, should be adopted when making treatment decisions.
Stage III, IVA and IVB
As discussed above for stages I and II, when managing Asian pa-
tients with stage III, IVA and IVB disease localized to the lip, patient
preference should be taken into account when determining the
appropriate course of treatment. For patients undergoing excision,
the panel recommends adjuvant weekly cisplatin (30–40 mg/m2)
in combination with RT as the subsequent therapy in patients with
T3/T4a N0 tumors. For any T and N1–3 disease, due to differences
in clinical practice, the 3-weekly cisplatin regimen remains op-
tional in Asia. For the unresectable patients or those considered
poor candidates for surgery, CCRT or cetuximab plus RT remain
the best alternative treatment options. The ESMO guidelines which
advocate surgery plus post-operative radiotherapy (including post-
operative chemoradiotherapy with single-agent platinum in pa-
tients with high risk features), should be followed in patients with
stage IVB resectable cancer of the lip.1
Oral cavity
Stage I, II, III and IVA
Treatment recommendations for Asian patients with stage I, II,
III and IVA oral cavity disease are the same as those advocated in
the NCCN V2 2011 guidelines.13 For patients with stage III and IV
tumors unsuitable for surgery or with unresectable disease, CCRT
or cetuximab plus RT are alternative options, and are preferable
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also be followed. However, for node positive cases neck dissection
is considered in case of residual disease in the neck with the pri-
mary controlled.
Stage IVB
Similar to locally advanced lip cancer, for patients with stage
IVB cancer of the oral cavity, the expert group agreed upon CCRT
or cetuximab plus RT as the preferred line of therapy, in line with
the NCCN and ESMO guidelines.1,13
Oropharynx
Stage I and II
For patients with oropharyngeal carcinoma and T1–2N0 dis-
ease, RT was recommended in preference to excision for Asian
practice. A surgical approach may be reserved for a highly select
group of patients with limited disease of the tonsil and good per-
formance status. This recommendation, based on expert opinion
and clinical practice, differs from the NCCN V2 2011 guideline,
where excision is given priority over RT.
Stage III, IVA, and IVB
For stage III, IVA and IVB disease, it was strongly recommended
to include RT plus systemic therapy as an alternative to RT alone
(i.e. cisplatin based CCRT or cetuximab plus RT). Sequential therapy
in the form of induction chemotherapy followed by deﬁnitive CCRT
continues to remain the subject of debate in this setting. After care-
ful consideration, the group recommends that induction chemo-
therapy could be undertaken in nodal disease N2–3 patients with
fairly good performance status at institutions or in clinical settings,
if effective supportive care is available, to manage treatment re-
lated morbidities. However, for the vast majority of patients, CCRT
or cetuximab plus RT is recommended as the mainstay of treat-
ment. For T3N2 disease, dissection of the neck is recommended,
in addition to RT plus systemic therapy. Although altered fraction-
ation radiation has been shown to offer some beneﬁt in oropharyn-
geal cancer, there are no additional advantages when administered
in combination with chemotherapy and is associated with greater
toxicity.10 Therefore, the group recommends standard fraction-
ation radiotherapy for these patients.
The group also discussed the importance of the prognostic or
predictive value associated with HPV in making treatment deci-
sions for HNC patients, especially for the oropharyngeal subsite.
The group stated that HPV analysis for serotypes 16 and 18 (or
p16 expression as surrogate marker) is not routinely recom-
mended for Asian practice based on clinical experience and a lack
of feasibility outside the clinical trial setting. However, it is
strongly advocated that HPV analysis subsets are incorporated in
future clinical trial settings to widen the scope of research and
make appropriate treatment decisions in the future, based on prog-
nostic or predictive association with choice of therapy.
Hypopharynx and larynx
Conforming to the NCCN guidelines, the discussion for this sub-
site is separated into glottic larynx, supraglottic larynx and
hypopharynx.
Glottic larynx
Deferring to the NCCN V2 2011 guidelines, the group recom-
mended stage 0 (carcinoma in situ) to be managed with endo-
scopic surgery. The group strongly recommends against open
surgery or radiotherapy in this situation. Over a number of years
in Asia, clinical experience has shown that these methods, when
used as a standard protocol, indiscriminately lead to considerablemorbidity in this patient population without an appreciable effect
on recurrence rates.
Stage I and II. The group recommends RT or endoscopic surgery
with carbon dioxide laser resection for this subset of patients.
The choice of treatment is decided on available infrastructure,
expertise and institutional preference.
Stage III. For T3 patients, the group recommends RT plus systemic
therapy (CCRT or cetuximab plus RT) or RT alone as the preferred
option. In patients considered for a surgical approach, inclusion
of partial laryngectomy as an alternative, in addition to total laryn-
gectomy with the possibility of ipsilateral thyroidectomy with or
without neck dissection in case of nodal involvement, is
recommended.
Stage IVA and IVB. For stage IVA (T3,N2–3) patients, the group
agrees with the NCCN V2 2011 guidelines which recommend RT
plus systemic therapy as the preferred treatment option, followed
by salvage surgery with or without neck dissection as the subse-
quent option. The group recommends that patients having non-
functional larynx or cartilage destruction, should be considered
for upfront a surgical treatment, laryngectomy or laryngopharyn-
gectomy, followed by adjuvant RT or CCRT, depending on the risk
of recurrence. For alternative organ preservation strategy, the
group recommended a taxane-platinum-5-FU (TPF) regimen, over
PF, followed by RT in highly selected patients.
Supraglottic larynx
Stage I and II. For Asian clinical practice, the group recommended
that radical RT is preferred over endoscopic or open partial laryn-
gectomy, in view of the complexity of surgery and relatively high
incidence of nodal relapse with no elective neck dissection.
Stage III, IVA and IVB. The group recommends a similar line of man-
agement for these patients as outlined under the glottic larynx for
the respective stages. In addition, most patients on an induction
TPF regimen will require supportive therapy and dosage reduction
may be considered, if necessary.
Hypopharynx
Stage I. The group agreed with the NCCN V2 2011 guidelines and
recommended RT as the mainstay treatment for this subset of pa-
tients. The group recommended against partial laryngopharygecto-
my/laser resection for stage I hypopharyngeal carcinoma the
rational being similar to that for early supraglottic laryngeal
cancers.
Stage II, III, IVA and IV B. Similar to the recommendations for glottic
and supraglottic larynx, the group recommended RT plus systemic
therapy as the preferred treatment option, speciﬁcally, CCRT is pre-
ferred over cetuximab plus RT. Again, surgery was preferred only in
cases where there is a non-functional larynx and in cases where
there is cartilage involvement. Induction CT with TPF is preferred
over a PF regimen for organ preservation strategies, when
considered.
For stages III and IV, hypopharynx and larynx, especially with
uninvolved cartilage, TPF induction chemotherapy, followed by
cetuximab plus radiation has shown similar results to concomitant
cisplatin plus radiotherapy in a single phase II study. This regimen
shows better patient compliance owing to avoidance of cumulative
cisplatin-related toxicities in the induction and concomitant
phases.16 However, lack of adequate data together with relatively
small patient numbers preclude the development of any deﬁnitive
conclusions regarding these results.
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and hypopharynx. For recurrent and metastatic disease, the group
strongly recommended a platinum-based combination therapy (2
drugs), preferably with cetuximab, in patients with metastatic dis-
ease and a performance status of 0 to 1.17 In case of non-affordabil-
ity issues, a two drug cisplatin based chemotherapy is a useful
alternative in patients with poor performance status or multiple
drug refractory disease, single agent chemotherapy drugs like plat-
inums, taxanes, methotrexate, ifosphamide, bleomycin, gemcita-
bine or cetuximab could be used.
Nasopharynx
For staging of nasopharyngeal cancers, the group recommends
that MRI scan is preferred over a CT scan, for detection of intra-cra-
nial extensions and retropharyngeal nodes metastasis.
Stage I. For Stage I disease, the group agrees with the NCCN V2
2011 guidelines for deﬁnitive RT to the nasopharynx with elective
RT to neck. To add to the dose of RT for elective neck irradiation to
uninvolved nodal stations, the group recommended a total 50–
60 Gy, which differs from the NCCN guidelines recommendation
of 44–64 Gy. Given the high incidence of NPC in Asian countries
there is signiﬁcant clinical experience to support the use of a high-
er radiation dose, which is more effective in preventing loco-regio-
nal recurrence. Based on the results of a retrospective study of 410
NPC patients with N0 disease, this expert group suggested to spare
the lower neck from elective irradiation.18
Stage II, III, IVA and IVB. For stage II and III (intermediate risk)
NPC,19–21 the group recommended CCRT as the preferred treatment
option. However, deferring to the NCCN V2 2011 guidelines, the
group commented that adjuvant chemotherapy may have a limited
role in these patients, and therefore may or may not be added to
CCRT depending on clinical experience. For higher stage (and high
risk) cases (stages III, IVA and IVB),22–24 although adjuvant CT is
generally recommended, in the absence of conclusive evidence,
the decision is to be judged based on individual clinical experience.
As highlighted in the ESMO guidelines, the choice between induc-
tion chemotherapy or a CCRT-based approach should be based on a
number of patient-related factors, including performance status
and tolerability issues.1 Guidelines also state that neither of these
treatment options appear to negatively impact survival outcomes
but they tend to lead to a reduction in distant metastases.1
For the high risk cases (stages III, IVA and IVB), cetuximab com-
bined with cisplatin and IMRT in locoregionally advanced nasopha-
ryngeal cancer, has demonstrated fairly good tolerability with
promising efﬁcacy.25,26 However, in the absence of larger, random-
ized phase III trials, comparing cetuximab combination versus cis-
platinum and IMRT, the group concluded that cetuximab based
combinations deserve further investigation prior to advocating
routine adoption in clinical practice. Until then, cisplatin in combi-
nation with IMRT is recommended for this group of patients.
Recurrent and/or persistent and M1 disease. For locally recurrent/
persistent disease, the group recommends a conﬁrmation biopsy
prior to re-treatment if the lesion is accessible. In occasional pa-
tients with locoregional recurrence/progression who have not
had prior RT, CCRT or RT alone is preferred over surgery. Salvage
surgery is recommended in a select group of patients with rela-
tively good performance status and a resectable tumor. For pa-
tients with locoregional recurrence/secondary primary, who have
undergone prior radiotherapy, re-irradiation should be considered
if relapse occurs after 1 year. For the rare patients with neck nodes
recurrence only, the group recommends that neck dissection is a
preferred salvage treatment option.As cited in the NCCN V2 2011 guidelines, platinum and taxane
combination therapy is preferred in patients with distant metasta-
ses and those unsuitable for re-irradiation of locoregional recur-
rences. The group also recommends other agents which have
shown activity in this group of patients which include paclitaxel,
docetaxel, infusional 5FU, gemcitabine, capecitabine, irinotecan,
vinorelbine, ifosfamide, doxorubicin and oxaliplatin, either as sin-
gle agents or in combination.
The group discussed the addition of cetuximab, with carbo-
platin in patients with recurrent/metastatic NPC who have failed
prior platinum-based therapies.27 Although preliminary results
do indicate a promising efﬁcacy and safety proﬁle for such a com-
bination, until randomised Phase III trials investigate this combina-
tion further, the expert panel does not recommend upfront usage
in clinical practice, but maintains, however, that it can be consid-
ered as an option in heavily pre-treated cases.
Pre-treatment plasma Epstein Barr Virus (EBV) DNA levels have
been shown to complement TNM staging in NPC,28 and elevated
EBV DNA levels at one week,29,30 or 6–8 weeks31 after treatment
is a powerful prognosticator of recurrence and survival. The group
recommends that EBV DNA can be used clinically to monitor dis-
ease response and recurrence in these patients depending on the
facilities available with the treating center.Conclusions
HNC remains prevalent in the Asian region and the majority of
patients will require multimodality treatment. Given the inherent
differences in the epidemiology, available resources, patient refer-
ral, and disease management processes in Asia, recommendations
or review articles of this nature become important and crucial to
understand and adopt international disease management guide-
lines for the management of Asian HNC patients. In summary,
the Expert Panel concluded that the management of HNC in the
Asian population is similar to the current NCCN and ESMO guide-
lines with some notable exceptions. The use of weekly cisplatin
rather than 3-weekly high dose cisplatin is recommended because
clinical experience demonstrates improved tolerability. In patients
with stage I–II oropharyngeal SCC, radiotherapy is favoured over
surgery and routine p16 analysis is not recommended outside of
the clinical trial setting. The overall management preference for
NPC differs from the NCCN and ESMO guidelines, in terms of deﬁn-
ing treatment strategies based on selecting patients associated
with risk factors. For stage 1 NPC, the panel recommends elective
nodal irradiation of 50–60 Gy rather than 44–64 Gy and omission
of lower neck elective irradiation. The elective nodal irradiation
dose of 50–60 Gy is common practice in Asian countries and is sup-
ported by population based institutional experience. This Expert
Panel strongly recommends creation and collaboration of cross
functional forums within countries, states and institutes to widen
the scope of selecting the right therapy for the right patient. The
panel also encourages the conduction of phase III randomized con-
trolled trials within the Asian continent. A multidisciplinary ap-
proach is essential to make appropriate treatment decisions,
particularly with regard to tolerability issues and quality of life.
The HNC management recommendations, discussed above, reﬂect
some of the best clinical practices within Asia and hopefully will
beneﬁt practitioners in planning and making decisions regarding
optimal treatment strategies for their patients.Conﬂict of interest statement
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